Skip to main content

Table 1 Study population

From: Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations

 

Males

Females

Total

n = 422

n = 334

Age

  

   Average ± SD

52.4 ± 20.9

54.8 ± 21.8

   0-12 months

n = 12

n = 8

   1-14 years old

n = 22

n = 13

   15-30 years old

n = 33

n = 24

   31-59 years old

n = 192

n = 142

   60-79 years old

n = 138

n = 108

   80 years old or older

n = 25

n = 39

Adult inpatient (not ICU a )

n = 287

n = 248

Pediatric inpatient (not ICU)

n = 19

n = 10

ICU

n = 88

n = 59

Emergency room

n = 5

n = 5

Primary care clinic

n = 4

n = 4

Other outpatient clinic

n = 15

n = 8

Monotherapy with phenytoin

n = 200

n = 171

One additional anti-epileptic drugs b

n = 176

n = 129

Two additional anti-epileptic drugs b

n = 38

n = 29

Three or more additional anti-epileptic drugs b

n = 8

n = 5

No seizures within 24 hrs of phenytoin drug level

n = 265

n = 228

Seizure(s) within 24 hrs of phenytoin drug level

n = 157

n = 106

  1. a ICU intensive care unit
  2. b Number of patients administered other anti-epileptic drugs: carbamazepine, 15; clonazepam, 5; diazepam, 10; felbamate, 9; lacosamide, 16; lamotrigine, 30; levetiracetam, 167; lorazepam, 56; pentobarbital, 14; phenobarbital, 51; primidone, 6; topiramate 19; valproic acid 44; zonisamide, 13